AR and prostate carcinoma: Because AR activation promotes the expression of CAMKK271, an AMPKα1 activator, it is possible that the synergistic effect of androgen on the killing of prostate cancer cells by YM155 also or alternatively occurs through enhanced activation of AMPKα by elevated levels of CAMKK2 induced by androgen.